|
|
Next Article 
Blood, Vol. 96 No. 3 (August 1), 2000:
pp. 785-793
PLENARY PAPER
Prolonged survival and tissue trafficking following adoptive
transfer of CD4 gene-modified autologous CD4+ and
CD8+ T cells in human immunodeficiency virus-infected
subjects
Ronald T. Mitsuyasu,
Peter A. Anton,
Steven G. Deeks,
David T. Scadden,
Elizabeth Connick,
Matthew T. Downs,
Andreas Bakker,
Margo R. Roberts,
Carl H. June,
Sayeh Jalali,
Andy A. Lin,
Rukmini Pennathur-Das, and
Kristen M. Hege
From the University of California, Los Angeles, CA; San Francisco
General Hospital, San Francisco, CA; Massachusetts General Hospital,
Boston, MA; University of Colorado Health Science Center, Denver, CO;
Statistics Collaborative, Washington DC; Specialty Labs, Los Angeles,
CA; University of Virginia, Charlottesville, VA; University of
Pennsylvania, Philadelphia, PA; and Cell Genesys, Inc, Foster City,
CA.
We have genetically engineered CD4+ and
CD8+ T cells with human immunodeficiency virus (HIV)
specificity by inserting a gene, CD4 , containing the extracellular
domain of human CD4 (which binds HIV env) linked to the zeta
() chain of the T-cell receptor (which mediates T-cell activation).
Twenty-four HIV-positive subjects received a single infusion of 2 to
3 × 1010 autologous CD4-modified CD4+
and CD8+ T cells administered with (n = 11) or
without (n = 13) interleukin-2 (IL-2). Subjects had CD4 counts
greater than 50/µL and viral loads of at least 1000 copies/mL at
entry. T cells were costimulated ex vivo through CD3 and CD28 and
expanded for approximately 2 weeks. CD4 was detected in 1% to 3%
of blood mononuclear cells at 8 weeks and 0.1% at 1 year after
infusion, and survival was not enhanced by IL-2. Trafficking of
gene-modified T cells to bulk rectal tissue and/or isolated lamina
propria lymphocytes was documented in a subset of 5 of 5 patients at 14 days and 2 of 3 at 1 year. A greater than 0.5 log mean decrease in
rectal tissue-associated HIV RNA was observed for at least 14 days,
suggesting compartmental antiviral activity of CD4 T cells.
CD4+ counts increased by 73/µL at 8 weeks in the group
receiving IL-2. There was no significant mean change in plasma HIV RNA
or blood proviral DNA in either treatment arm. This sustained,
high-level persistence of gene-modified T cells demonstrates the
feasibility of ex vivo T-cell gene therapy in HIV-infected adults and
suggests the importance of providing HIV-specific T-helper function.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Jing, J. A. Gershan, and B. D. Johnson
Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory
Blood,
April 30, 2009;
113(18):
4449 - 4457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Frecha, C. Costa, D. Negre, E. Gauthier, S. J. Russell, F.-L. Cosset, and E. Verhoeyen
Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins
Blood,
December 15, 2008;
112(13):
4843 - 4852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Newrzela, K. Cornils, Z. Li, C. Baum, M. H. Brugman, M. Hartmann, J. Meyer, S. Hartmann, M.-L. Hansmann, B. Fehse, et al.
Resistance of mature T cells to oncogene transformation
Blood,
September 15, 2008;
112(6):
2278 - 2286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Moisini, P. Nguyen, L. Fugger, and T. L. Geiger
Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-{zeta} Chimeric Receptor
J. Immunol.,
March 1, 2008;
180(5):
3601 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Moeller, M. H. Kershaw, R. Cameron, J. A. Westwood, J. A. Trapani, M. J. Smyth, and P. K. Darcy
Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CD8+ T Cells
Cancer Res.,
December 1, 2007;
67(23):
11428 - 11437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Savoldo, C. M. Rooney, A. Di Stasi, H. Abken, A. Hombach, A. E. Foster, L. Zhang, H. E. Heslop, M. K. Brenner, and G. Dotti
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
Blood,
October 1, 2007;
110(7):
2620 - 2630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Landmeier, B. Altvater, S. Pscherer, B. R. Eing, J. Kuehn, C. M. Rooney, H. Juergens, and C. Rossig
Gene-Engineered Varicella-Zoster Virus Reactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function
Cancer Res.,
September 1, 2007;
67(17):
8335 - 8343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Connick, T. Mattila, J. M. Folkvord, R. Schlichtemeier, A. L. Meditz, M. G. Ray, M. D. McCarter, S. MaWhinney, A. Hage, C. White, et al.
CTL Fail to Accumulate at Sites of HIV-1 Replication in Lymphoid Tissue
J. Immunol.,
June 1, 2007;
178(11):
6975 - 6983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Biagi, V. Marin, G. M. P. Giordano Attianese, E. Dander, G. D'Amico, and A. Biondi
Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
Haematologica,
March 1, 2007;
92(3):
381 - 388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Moeller, N. M. Haynes, M. H. Kershaw, J. T. Jackson, M. W. L. Teng, S. E. Street, L. Cerutti, S. M. Jane, J. A. Trapani, M. J. Smyth, et al.
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection
Blood,
November 1, 2005;
106(9):
2995 - 3003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Mekala, R. S. Alli, and T. L. Geiger
IL-10-Dependent Suppression of Experimental Allergic Encephalomyelitis by Th2-Differentiated, Anti-TCR Redirected T Lymphocytes
J. Immunol.,
March 15, 2005;
174(6):
3789 - 3797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Brainard, W. G. Tharp, E. Granado, N. Miller, A. K. Trocha, X.-H. Ren, B. Conrad, E. F. Terwilliger, R. Wyatt, B. D. Walker, et al.
Migration of Antigen-Specific T Cells Away from CXCR4-Binding Human Immunodeficiency Virus Type 1 gp120
J. Virol.,
May 15, 2004;
78(10):
5184 - 5193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Finney, A. N. Akbar, and A. D. G. Lawson
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCR{zeta} Chain
J. Immunol.,
January 1, 2004;
172(1):
104 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Nguyen, I. Moisini, and T. L. Geiger
Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function
Blood,
December 15, 2003;
102(13):
4320 - 4325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Thompson, R. A. Figlin, C. Sifri-Steele, R. J. Berenson, and M. W. Frohlich
A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma
Clin. Cancer Res.,
September 1, 2003;
9(10):
3562 - 3570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al.
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Science,
October 25, 2002;
298(5594):
850 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Lin and M. R. Roberts
Developmental dissociation of T cells from B, NK, and myeloid cells revealed by MHC class II-specific chimeric immune receptors bearing TCR-zeta or FcR-gamma chain signaling domains
Blood,
September 26, 2002;
100(8):
3045 - 3048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, H.-G. Klingemann, and W. Wels
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction
Blood,
July 30, 2002;
100(4):
1265 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy
Blood,
March 15, 2002;
99(6):
2009 - 2016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Villinger, G. T. Brice, A. E. Mayne, P. Bostik, K. Mori, C. H. June, and A. A. Ansari
Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4+ cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status
Blood,
January 15, 2002;
99(2):
590 - 599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Geiger, P. Nguyen, D. Leitenberg, and R. A. Flavell
Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes
Blood,
October 15, 2001;
98(8):
2364 - 2371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Levine, D. T. Scadden, J. A. Zaia, and A. Krishnan
Hematologic Aspects of HIV/AIDS
Hematology,
January 1, 2001;
2001(1):
463 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
